Plant Name: Akebia quinata
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPBAR1; FFAR1; FFAR4; | |
| TSHR; | |
| PTPN1; PTPN2; CDC25B; | |
| PLA2G1B; HPGD; AKR1B1; AKR1B10; ALOX15; ALDH1A1; POLB; | |
| TRPA1; | |
| MAPK1; PRKCA; | |
| CA4; CA6; | |
| PPARA; PPARD; PPARG; | |
| NR1H4; | |
| PTGS1; XDH; | |
| CASP1; CASP7; | |
| TLR2; | |
| HIF1A; TP53; | |
| SLC22A8; SLC22A6; SLCO1B3; SLCO1B1; | |
| LMNA; FABP3; FABP5; FABP2; FABP4; MAPT; APP; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | PRKCA | Protein kinase C alpha | P17252 | CHEMBL299 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| SLC superfamily of solute carriers | SLC22A8 | Solute carrier family 22 member 8 | Q8TCC7 | CHEMBL1641348 |
| SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transient receptor potential channel | TRPA1 | Transient receptor potential cation channel subfamily A member 1 | O75762 | CHEMBL6007 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 2.284E-07 | 8.469E-05 | CA4, HPGD, SLC22A6, SLC22A8, SLCO1B1, SLCO1B3, TSHR |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 2.632E-07 | 9.269E-05 | FFAR4, NR1H4, PPARA, PPARD, PPARG, PTPN2 |
| MF | GO:0005215; transporter activity | GO:0015347; sodium-independent organic anion transmembrane transporter activity | 2.639E-07 | 9.269E-05 | SLC22A6, SLC22A8, SLCO1B1, SLCO1B3 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 3.136E-07 | 1.067E-04 | FABP2, FABP3, FABP4, FABP5 |
| BP | GO:0051179; localization | GO:0043252; sodium-independent organic anion transport | 5.051E-07 | 1.549E-04 | SLC22A6, SLC22A8, SLCO1B1, SLCO1B3 |
| BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 1.152E-06 | 3.022E-04 | FABP3, FFAR1, NR1H4, PPARG, TLR2 |
| BP | GO:0065007; biological regulation | GO:0006919; activation of cysteine-type endopeptidase activity involved in apoptotic process | 1.303E-06 | 3.338E-04 | CASP1, CASP7, MAPT, PPARG, XDH |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 1.540E-06 | 3.768E-04 | AKR1B1, AKR1B10, APP, CYP2A6, CYP3A4, NR1H4, PPARD |
| MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 3.259E-06 | 6.758E-04 | AKR1B1, AKR1B10, ALDH1A1, XDH |
| BP | GO:0050896; response to stimulus | GO:0009636; response to toxic substance | 3.607E-06 | 7.272E-04 | AKR1B1, HPGD, MAPK1, POLB, SLC22A8, TLR2, TP53, TRPA1 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 4.893E-06 | 9.775E-04 | AKR1B1, AKR1B10, ALDH1A1, ALOX15, CYP2A6, CYP3A4, HPGD, PPARD, PPARG, PTGS1, XDH |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 5.043E-06 | 9.894E-04 | NR1H4, PPARA, PPARD, PPARG |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 5.280E-06 | 1.017E-03 | AKR1B1, AKR1B10, ALDH1A1, ALOX15, APP, CASP1, CASP7, CDC25B, FABP2, FABP3, FABP4, FABP5, HIF1A, HPGD, LMNA, MAPK1, MAPT, PLA2G1B, PPARG, PRKCA, PTPN1, PTPN2, SMN1, SMN2, TP53, XDH |
| BP | GO:0050896; response to stimulus | GO:1901653; cellular response to peptide | 8.325E-06 | 1.511E-03 | AKR1B1, APP, PLA2G1B, PPARG, TP53, TSHR |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 1.065E-05 | 1.841E-03 | NR1H4, PPARA, PPARD, PPARG |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.526E-05 | 2.480E-03 | POLB, PPARG, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0014005; microglia development | 1.590E-05 | 2.527E-03 | APP, TLR2 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 1.590E-05 | 2.527E-03 | GPBAR1, NR1H4 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 1.590E-05 | 2.527E-03 | GPBAR1, NR1H4 |
| BP | GO:0050896; response to stimulus | GO:0032868; response to insulin | 1.740E-05 | 2.726E-03 | FABP3, PLA2G1B, PPARA, PPARG, TLR2 |
| CC | GO:0044464; cell part | GO:0032838; plasma membrane bounded cell projection cytoplasm | 1.770E-05 | 2.733E-03 | AKR1B1, HIF1A, MAPK1, MAPT |
| BP | GO:0023052; signaling | GO:0032024; positive regulation of insulin secretion | 1.877E-05 | 2.858E-03 | FFAR1, HIF1A, NR1H4, PPARD |
| BP | GO:0009987; cellular process | GO:0043410; positive regulation of MAPK cascade | 2.068E-05 | 3.085E-03 | ALOX15, APP, FFAR4, MAPK1, PLA2G1B, PRKCA, PTPN1, XDH |
| BP | GO:0008152; metabolic process | GO:0009299; mRNA transcription | 2.622E-05 | 3.707E-03 | HIF1A, PPARD, TP53 |
| BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 3.072E-05 | 4.155E-03 | ALOX15, PPARA, PPARD, TP53 |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 3.175E-05 | 4.190E-03 | PTPN1, PTPN2 |
| BP | GO:0032501; multicellular organismal process | GO:0032640; tumor necrosis factor production | 3.175E-05 | 4.190E-03 | APP, TLR2 |
| BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 3.323E-05 | 4.333E-03 | FFAR1, HIF1A, NR1H4, PPARG, PTPN2 |
| MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 3.716E-05 | 4.677E-03 | MAPT, PTPN1, TP53 |
| BP | GO:0009987; cellular process | GO:0070372; regulation of ERK1 and ERK2 cascade | 3.948E-05 | 4.913E-03 | ALOX15, APP, FFAR4, PRKCA, PTPN1, PTPN2 |
| BP | GO:0008152; metabolic process | GO:0006066; alcohol metabolic process | 4.112E-05 | 5.072E-03 | AKR1B1, AKR1B10, ALDH1A1, APP, CYP3A4, PPARD |
| BP | GO:0051179; localization | GO:0015721; bile acid and bile salt transport | 4.590E-05 | 5.492E-03 | NR1H4, SLCO1B1, SLCO1B3 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 5.074E-05 | 5.972E-03 | ALOX15, PLA2G1B, TLR2 |
| BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 5.283E-05 | 6.120E-03 | PPARA, PPARG |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 7.101E-05 | 7.987E-03 | AKR1B1, CASP7, CDC25B, FABP5, HIF1A, HPGD, LMNA, MAPK1, NR1H4, POLB, PPARA, PPARD, PPARG, PRKCA, PTPN2, SMN1, SMN2, TP53 |
| BP | GO:0051179; localization | GO:0010887; negative regulation of cholesterol storage | 7.913E-05 | 8.530E-03 | PPARA, PPARG |
| BP | GO:0009987; cellular process | GO:0060336; negative regulation of interferon-gamma-mediated signaling pathway | 7.913E-05 | 8.530E-03 | PPARG, PTPN2 |
| BP | GO:0008152; metabolic process | GO:0010871; negative regulation of receptor biosynthetic process | 7.913E-05 | 8.530E-03 | PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 7.913E-05 | 8.530E-03 | ALOX15, HPGD |
| MF | GO:0005488; binding | GO:0050543; icosatetraenoic acid binding | 7.913E-05 | 8.530E-03 | FABP3, PPARG |
| BP | GO:0008152; metabolic process | GO:0046456; icosanoid biosynthetic process | 8.685E-05 | 9.317E-03 | ALOX15, PLA2G1B, PTGS1 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 8.982E-05 | 9.587E-03 | CA4, CA6, NR1H4, PPARA, PPARD, PPARG, PRKCA, PTPN1, TP53 |
| BP | GO:0050896; response to stimulus | GO:0010038; response to metal ion | 9.165E-05 | 9.709E-03 | ALOX15, APP, FABP4, HIF1A, MAPK1, TP53 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 1.741E-10 | 2.837E-08 | FABP2; FABP3; FABP4; FABP5; PPARG; PPARA; PPARD |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 5.346E-07 | 4.357E-05 | SLCO1B1; SLCO1B3; NR1H4; SLC22A8; CYP3A4 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 5.144E-06 | 2.795E-04 | APP; ALOX15; MAPK1; PRKCA; PTGS1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 9.007E-05 | 2.097E-03 | MAPK1; PRKCA; TP53; HIF1A; TLR2 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 3.733E-05 | 1.217E-03 | MAPK1; PPARG; TP53 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.733E-05 | 1.217E-03 | PLA2G1B; ALOX15; CYP3A4 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 2.493E-04 | 2.980E-03 | MAPK1; PRKCA; PPARG; HIF1A; TP53; PPARD |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.423E-04 | 2.735E-03 | MAPK1; PRKCA; TP53; HIF1A |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 2.610E-04 | 2.980E-03 | MAPK1; PRKCA; MAPT; TP53; CDC25B |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 2.742E-04 | 2.980E-03 | CASP7; LMNA; MAPK1; TP53 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.510E-04 | 2.735E-03 | CYP2A6; CYP3A4; XDH |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 2.714E-04 | 2.980E-03 | MAPK1; PRKCA; TP53 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 3.218E-04 | 3.193E-03 | MAPK1; PRKCA; TP53; TLR2 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 2.573E-04 | 2.980E-03 | CASP7; CASP1; TLR2 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 2.714E-04 | 2.980E-03 | FABP4; TSHR; PTGS1 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 3.330E-04 | 3.193E-03 | MAPK1; PRKCA; HIF1A |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 4.217E-04 | 3.437E-03 | MAPK1; PRKCA; TP53 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 3.669E-04 | 3.322E-03 | PLA2G1B; ALOX15; PTGS1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 5.472E-04 | 4.054E-03 | APP; CASP7; MAPK1; MAPT |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 4.217E-04 | 3.437E-03 | CYP2A6; ALDH1A1; CYP3A4 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 4.611E-04 | 3.579E-03 | MAPK1; TP53; HIF1A |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.525E-03 | 9.558E-03 | CYP2A6; AKR1B10; PLA2G1B; ALOX15; ALDH1A1; AKR1B1; CYP3A4; XDH; PTGS1 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 1.521E-03 | 9.558E-03 | MAPK1; PRKCA; HIF1A |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 6.418E-04 | 4.475E-03 | CASP7; CASP1; MAPK1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.609E-03 | 9.712E-03 | MAPK1; PRKCA; HIF1A |
| hsa04270 | Vascular smooth muscle contraction_Homo sapiens_hsa04270 | 2.488E-03 | 1.308E-02 | PLA2G1B; MAPK1; PRKCA |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 2.488E-03 | 1.308E-02 | MAPK1; PRKCA; TP53 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 3.327E-03 | 1.643E-02 | MAPK1; PPARA; TP53 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 4.400E-03 | 1.887E-02 | MAPK1; PRKCA; TP53; CDC25B |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 3.998E-03 | 1.761E-02 | PRKCA; TP53; PPARD |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 7.137E-03 | 2.706E-02 | MAPK1; PRKCA; TP53; TLR2 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 7.137E-03 | 2.706E-02 | CASP1; MAPK1; PRKCA |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 7.710E-03 | 2.767E-02 | HPGD; PPARG; TP53 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.013E-02 | 3.098E-02 | MAPK1; PPARA; TSHR |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 4.929E-05 | 1.339E-03 | CYP2A6; XDH |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.098E-02 | 3.133E-02 | POLB; MAPK1; TP53 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.442E-02 | 3.732E-02 | PLA2G1B; MAPK1; PRKCA |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 6.111E-03 | 2.490E-02 | MAPK1; TP53 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 7.303E-03 | 2.706E-02 | MAPK1; PPARD |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 8.327E-03 | 2.828E-02 | MAPK1; PRKCA |
| hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 8.065E-03 | 2.797E-02 | MAPK1; PRKCA |
| hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 3.479E-03 | 1.668E-02 | MAPK1; PRKCA |
| hsa05014 | Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | 5.885E-03 | 2.459E-02 | CASP1; TP53 |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 1.026E-02 | 3.098E-02 | MAPK1; PRKCA |
| hsa04720 | Long-term potentiation_Homo sapiens_hsa04720 | 9.691E-03 | 3.038E-02 | MAPK1; PRKCA |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 7.303E-03 | 2.706E-02 | CASP1; MAPK1 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 3.839E-03 | 1.738E-02 | MAPK1; TP53 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 9.691E-03 | 3.038E-02 | MAPK1; HIF1A |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 9.691E-03 | 3.038E-02 | MAPK1; TP53 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 8.592E-03 | 2.858E-02 | MAPK1; TP53 |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 7.807E-03 | 2.767E-02 | AKR1B10; AKR1B1 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 2.069E-03 | 1.204E-02 | AKR1B10; AKR1B1 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.115E-02 | 3.133E-02 | MAPK1; TP53 |
| hsa04975 | Fat digestion and absorption_Homo sapiens_hsa04975 | 3.839E-03 | 1.738E-02 | FABP2; PLA2G1B |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.176E-02 | 3.141E-02 | MAPK1; TP53 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 1.176E-02 | 3.141E-02 | MAPK1; TLR2 |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 1.641E-02 | 3.991E-02 | MAPK1; PRKCA |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.055E-02 | 3.128E-02 | CYP2A6; CYP3A4 |
| hsa04911 | Insulin secretion_Homo sapiens_hsa04911 | 1.570E-02 | 3.937E-02 | PRKCA; FFAR1 |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 1.786E-02 | 4.158E-02 | MAPK1; PRKCA |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.712E-02 | 4.045E-02 | MAPK1; TP53 |
| hsa04918 | Thyroid hormone synthesis_Homo sapiens_hsa04918 | 1.115E-02 | 3.133E-02 | PRKCA; TSHR |
| hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 1.860E-02 | 4.270E-02 | MAPK1; PRKCA |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 2.052E-02 | 4.401E-02 | MAPK1; CDC25B |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.898E-02 | 4.297E-02 | PPARG; TP53 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 2.171E-02 | 4.424E-02 | MAPK1; PRKCA |
| hsa04713 | Circadian entrainment_Homo sapiens_hsa04713 | 1.936E-02 | 4.323E-02 | MAPK1; PRKCA |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.176E-02 | 3.141E-02 | CYP2A6; CYP3A4 |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 2.052E-02 | 4.401E-02 | TRPA1; PRKCA |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 2.352E-03 | 1.308E-02 | AKR1B10; AKR1B1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 2.971E-03 | 1.513E-02 | AKR1B10; AKR1B1 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 1.676E-02 | 4.018E-02 | MAPK1; PRKCA |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.206E-02 | 3.172E-02 | PTPN1; MAPK1 |
| hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 2.131E-02 | 4.424E-02 | MAPK1; PRKCA |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.467E-02 | 3.735E-02 | CYP2A6; CYP3A4 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 1.605E-02 | 3.964E-02 | CASP1; MAPK1 |
| hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 1.974E-02 | 4.349E-02 | PLA2G1B; PRKCA |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 2.131E-02 | 4.424E-02 | PRKCA; TLR2 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 2.376E-02 | 4.722E-02 | MAPK1; TLR2 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 2.502E-02 | 4.914E-02 | PTPN1; PPARA |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 2.545E-02 | 4.938E-02 | CASP7; MAPK1 |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 2.588E-02 | 4.963E-02 | MAPK1; PRKCA |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 2.293E-02 | 4.614E-02 | MAPK1; TLR2 |
| hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 2.171E-02 | 4.424E-02 | MAPK1; PRKCA |
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 6.589E-04 | 4.475E-03 | CA4; CA6 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT; APP; PPARG; PPARG |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; MAPK1; TLR2 |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; PTGS1 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PLA2G1B; PTGS1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PPARG |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; PPARD; PPARD; PPARG |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | APP |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| NA: NA | Dyslipidemia | NA | PPARD |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4 |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1 |
| C00-D49: Neoplasms | Glioma | C71 | APP |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; XDH; PPARG |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | APP |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; FFAR1; AKR1B1; PPARG |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1 |
| NA: NA | Rheumatold arthritis | NA | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; PTGS1 |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; GPBAR1; FFAR1; PPARD; PPARG; PPARG |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; TP53; MAPK1; TLR2; CDC25B; APP |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B |
| C00-D49: Neoplasms | Prostate cancer | C61 | TLR2 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD; MAPT |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CASP1; AKR1B1; PLA2G1B |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | PTGS1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| NA: NA | Geographic retinal atrophy | NA | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | TRPA1; PTGS1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
| J00-J99: Diseases of the respiratory system | Throat irritation | J39.2 | TRPA1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PPARG |